These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 446504)

  • 21. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary metastases, an occult prostatic adenocarcinoma and delayed administration of antiandrogens.
    Harris SJ; Cowley N
    Clin Oncol (R Coll Radiol); 1996; 8(2):118-9. PubMed ID: 8859611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
    Senn E; Müller J; Alioth H
    Schweiz Rundsch Med Prax; 1985 Nov; 74(48):1340-4. PubMed ID: 3003863
    [No Abstract]   [Full Text] [Related]  

  • 24. [Proceedings: Value of cyproterone in the treatment of prostatic cancers with metastases].
    Bracci U
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):405-6. PubMed ID: 4804409
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of prostatic cancer].
    J Urol (Paris); 1984; 90(10):619-48. PubMed ID: 6242517
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
    Schröder FH; Collette L; de Reijke TM; Whelan P
    Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 28. Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report.
    Varenhorst E; Björnlert U; Carlström K
    Scand J Urol Nephrol; 1981; 15(2):157-9. PubMed ID: 7330610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A morphological study on the effect of cyproterone acetate on human prostatic carcinoma.
    Tveter KJ; Attramadal A; Hannestad R; Otnes B
    Scand J Urol Nephrol; 1979; 13(3):237-43. PubMed ID: 531525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of cyproterone acetate in prostate cancer.
    Goldenberg SL; Bruchovsky N
    Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.
    Morrison BF; Aiken WD; Reid ME
    Rev Panam Salud Publica; 2011 Jun; 29(6):404-8. PubMed ID: 21829963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis of prostatic cancer.
    Arvola I; Lilius HG; Uusi-Penttilä S
    Ann Chir Gynaecol Fenn; 1972; 61(1):25-9. PubMed ID: 5021539
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical applications of antiandrogens.
    Namer M
    J Steroid Biochem; 1988 Oct; 31(4B):719-29. PubMed ID: 2462132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer.
    Pescatore D; Giberti C; Martorana G; Natta G; Giuliani L
    Eur Urol; 1980; 6(3):149-53. PubMed ID: 7371660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palliative effect of cyproterone acetate in carcinoma of the prostate with widespread metastatic bone disease.
    Fox M; Hammonds JC
    Br J Urol; 1980 Oct; 52(5):402. PubMed ID: 7427019
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of prostatic cancer. Newer forms of androgen deprivation.
    Soloway MS
    Postgrad Med; 1986 Jul; 80(1):249-52, 257-8. PubMed ID: 2941729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cancer of the prostate: subcapsular orchiectomy].
    Cukier J; Rivain T
    Bull Cancer; 1985; 72(6):543-8. PubMed ID: 4092105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.